Untitled

Abstract

Objective: While the incidence of sarcoidosis peaks between 20 and 39 years, it is comparatively low in elderly subjects. We sought to determine whether there are age-dependent differences in the demographic and laboratory characteristics of patients with sarcoidosis. Materials and Methods: We retrospectively collected information from our database using the International Classification of Disease (ICD) diagnostic code D86 between 2008 and 2014. Patients were divided into three groups: 20-39 years old (Group 1), 40-59 years old (Group 2), and 60-80 years old (Group 3). Results: A total of 3988 patients with code of D86 were included in the study. After the exclusion of noneligible patients, the number of cases in Groups 1, 2, and 3 were 276, 641, and 352, respectively. The groups were compared according to demographic characteristics, ICD diagnostic codes, and laboratory parameters. The ratio of female patients was significantly higher in Group 3 than in Groups 1 and 2 (p=0.000). There was no difference in diagnostic codes of the ICD subgroups between groups (p=0.19). While the level of bloodurea nitrogen was significantly higher in Group 3 patients than in other groups (p=0.000), serum angiotensinconverting enzyme (ACE) values were found to be significantly low in Group 3 (p=0.010). The mean ACE values did not differ between females and males (50.8±39.3 and 59.1±45.5 mg/dL, respectively) (p=0.18). Conclusion:The majority of patients with sarcoidosis were female in all age groups and pulmonary sarcoidosis was the most common presentation of the disease. Elderly patients (≥60 years) with sarcoidosis had lower serum ACE levels than younger patients.

Linking Immunological Parameters and Recovery of Patient’s Motor and Cognitive Functions In The Acute Period of Ischemic Stroke

“…Результаты исследований иммунологического статуса у больных с ИИ демонстрируют прямую связь экспрессии хемокинов подсемейства CC -CCL3 (MIP-1α), CCL5 (RANTES), CCL7 (MCP-3), CCL13 (MCP-4), CCL14 (HCC-1), CCL15 (LKN-1) и CCL23 (MPIF-1) с тяжестью инсульта [12][13][14]. Хемокинами подсемейства CXC, наиболее связанными с механизмами ишемии, являются CXCL1 (Gro-a), CXCL-2 (Gro-b), CXCL9 (MIG), CXCL10 (IP-10), CXCL11(I-TAC), CXCL12 (SDF-1a+b) CXCL16 (SCYB16) и CXCL8 (IL-8) [15]. Понимание процессов дифференциальной экспрессии цитокинов различных подсемейств у пациентов в остром периоде инсульта позволит расширить представление о роли иммунного ответа в патогенезе ИИ, а также выделить отдельные цитокины или их комбинации в качестве потенциальных биомаркеров оценки тяжести ишемии и стратификации риска неблагоприятного исхода после инсульта.…”